MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD

Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

GAITHERSBURG, MD, April 12, 2022 - MaxCyte,

Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to

advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today

announced that Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other

interests. Ron Holtz, current Senior Vice President and Chief Accounting Officer, has been named Interim Chief Financial Officer effective

upon Ms. Murphy's departure.

Following her departure, Ms. Murphy intends to

provide consulting services to MaxCyte as requested to facilitate a smooth transition of responsibilities. Additionally, Sean Menarguez

has been promoted to Director, Investor Relations.

MaxCyte also announced that its revenue for

the first quarter of 2022 is expected to be at least $11.0 million, compared to $6.5 million in the first quarter of 2021. Core

business revenue is expected to be at least $9.0 million, compared to $6.5 million in the prior year period, and SPL Program-related

revenue is expected to be $2.0 million, compared to $0.0 in the prior year period. These results are preliminary, however, and remain subject to the completion of

MaxCyte's normal quarterly review procedures. As a result, these preliminary results may be different from the actual results

that will be reflected in MaxCyte's consolidated financial statements for the quarter ended March 31, 2022, which are expected

to be released in May.

"On behalf of our entire team, I would like

to thank Amanda for her contributions to MaxCyte, helping guide us through our initial public offering on Nasdaq in early August of last

year and seeing us through our continued strong growth. We wish her well in her future endeavors," said Doug Doerfler, President

and CEO of MaxCyte. "I am pleased to announce the appointment of Ron as our CFO on an interim basis; previously, Ron served as MaxCyte's

CFO from 2005 to 2020 and has remained an integral part of our management team while serving as Chief Accounting Officer. Additionally,

I am delighted with our operational and financial performance in the first quarter, and proud of our continued successful support for

the clinical progress of our partners."

"It has been an honor to serve as CFO of

MaxCyte and participate in the company's growth, strategy development and successful IPO on the Nasdaq exchange," said Amanda

Murphy. "I remain committed to ensuring a smooth transition and look forward to working with Ron and the finance team over the coming

The Company has engaged executive search firm

Korn Ferry to lead a search for a new Chief Financial Officer.

is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative

cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past

20 years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex

engineering of a wide variety of cells. Our ExPERT platform, which is based on our Flow Electroporation technology, has

been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the

high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines.

The ExPERT family of products includes: four instruments, the ATx , STx GTx and VLx ; a

portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide

intellectual property portfolio.

Forward-Looking Statements

press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private

Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our management transition and our expected

revenue for the quarter ended March 31, 2022. The words "may," "might," "will," "could," "would,"

"should," "expect," "plan," "anticipate," "intend," "believe," "expect,"

"estimate," "seek," "predict," "future," "project," "potential," "continue,"

"target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking

statements contain these identifying words.

forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number

of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied

by any forward-looking statements contained in this press release, including, without limitation, the timing of our customers' ongoing

and planned clinical trials and general market and economic conditions. These and other risks and uncertainties are described in greater

detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, filed

with the Securities and Exchange Commission on March 22, 2022, as well as discussions of potential risks, uncertainties, and other important

factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available

under the "SEC filings" page of the Investors section of our website at http://investors.maxcyte.com.

forward-looking statements represent our views only as of the date of this press release and should not be relied upon as representing

our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result

of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of

any such forward-looking statements.